- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 19.10. | Saudi Arabia takes actionable steps to build its biotech sector after 46 agreements in Riyadh | ||
| 19.10. | Roche returns to China's ADC powerhouse Hansoh for $15B biobucks pact | ||
| 19.10. | Immune Boost Capital Invests in Orthrus Therapeutics to Advance Antigen-Specific Immune Tolerance for Autoimmune Disease | ||
| 19.10. | Siemens Healthineers partners with Paradromics to build out new imaging system to support BCIs | ||
| 19.10. | Beyond Amyloid: New Insights into Tau Pathology and Disease Progression with eMTBR | ||
| 19.10. | AbbVie's next-gen Crohn's disease combo beats Skyrizi in phase 2 trial | ||
| 19.10. | Nouscom raises $135M for pivotal trial of cancer-preventing vaccine candidate | ||
| 16.10. | Aligning drug discovery around patient benefit from the outset: Connecting human insights to better decisions | ||
| 16.10. | From Scientific Hypothesis to Clinical Practice: The Next Chapter for CLDN18.2 | ||
| 16.10. | China looks to ban foreign acquisitions of critical biopharma platforms | ||
| 16.10. | FDA issues early alert for Edwards Lifesciences' mitral valve delivery system after reported death, injury | ||
| 16.10. | Chutes & Ladders-Bausch + Lomb's returning CEO Saunders exits again | ||
| 16.10. | SimBioSys nabs FDA clearance for Nvidia-powered, MRI-derived breast cancer recurrence tool | ||
| 16.10. | 'It's certainly not easy': How are Boston biotechs coping with a shallower pool of seed funding? | ||
| 16.10. | Estuary flows out of stealth with $103M to propel kidney disease gene therapies into clinic | ||
| 16.10. | City goes public with $200M IPO, while Frazier Life Sciences takes biotech-focused SPAC to Nasdaq | ||
| 15.10. | OrbiMed's largest-ever Asian fund contributes to $3B war chest | ||
| 15.10. | Osivax focuses on combo strategy for flu vaccine after phase 2 fail | ||
| 15.10. | AstraZeneca inks $1.5B insitro deal for AI-enabled target discovery of liver, heart disease drugs | ||
| 15.10. | Lakefront Biotherapeutics finally finds buyer for unwanted cell therapy pipeline | ||
| 15.10. | Vanda pauses social anxiety program after ex-Novartis asset flunks phase 3 study | ||
| 15.10. | Iambic goes public with $150M IPO to accelerate clinical development of oncology pipeline | ||
| 15.10. | Why OMass' $310M series C marks 'fantastic milestone' on journey to become 'Britain's Big Biotech' | ||
| 14.10. | Merck KGaA spinout iOnctura touts PI3K delta inhibitor in metastatic eye cancer | ||
| 14.10. | IQVIA, Veeva expand on existing partnership for speedier clinical trials |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.